Outcome | Group | Improvement | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
T0 to T1 (immediately after treatment) | T0 to T2 (6Ā months after treatment) | T0 to T3 (12Ā months after treatment) | ||||||||
Mean (SD) | B | 95% CI | Mean (SD) | B | 95% CI | Mean (SD) | B | 95% CI | ||
SDQa (Ī±ā=ā0.60) | UC | 0.96āĀ±ā4.34 | 0.77 | ā1.37 to 2.91 | 0.96āĀ±ā5.44 | 1.94 | ā0.30 to 4.19 | 2.29āĀ±ā5.96 | 1.59 | ā0.56 to 3.76 |
I | 2.74āĀ±ā4.04 | 3.57āĀ±ā4.93 | 4.19āĀ±ā5.0 | |||||||
ECBIa (Ī±ā=ā0.87) | UC | 1.81āĀ±ā13.48 | 4.99 | ā3.63 to 13.64 | 2.74āĀ±ā13.62 | 5.81 | ā3.37 to 14.99 | 9.22āĀ±ā17.71 | 5.18 | ā3.59 to 13.97 |
I | 8.53āĀ±ā22.07 | 10.67āĀ±ā19.24 | 15.29āĀ±ā24.35 | |||||||
PSb (Ī±ā=ā0.84) | UC | 0.05āĀ±ā0.40 | 0.13 | ā0.04 to 0.31 | 0.04āĀ±ā0.37 | 0.02 | ā0.17 to 0.21 | 0.02āĀ±ā0.49 | 0.10 | ā0.07 to 0.29 |
I | 0.26āĀ±ā0.37 | 0.15āĀ±ā0.35 | 0.20āĀ±ā0.46 | |||||||
PSIb (Ī±ā=ā0.88) | UC | 1.21āĀ±ā6.00 | 2.75 | ā0.87 to 6.37 | 0.66āĀ±ā6.97 | ā0.51 | ā4.41 to 3.38 | ā1.35āĀ±ā9.59 | 2.18 | ā1.51 to 5.89 |
I | 4.93āĀ±ā9.09 | 1.10āĀ±ā5.49 | 1.96āĀ±ā8.71 | |||||||
PSBCb (Ī±ā=ā0.97) | UC | ā0.20āĀ±ā1.71 | ā0.54 | ā1.20 to 0.10 | 0.28āĀ±ā0.90 | ā0.04 | ā0.71 to 0.62 | 0.31āĀ±ā0.92 | ā0.39 | ā1.05 to 0.26 |
I | 0.82āĀ±ā1.42 | 0.55āĀ±ā1.67 | 0.84āĀ±ā1.47 | |||||||
DASSb (Ī±ā=ā0.94) | UC | 3.21āĀ±ā10.33 | ā5.80 | ā12.28 to 0.67 | 3.55āĀ±ā14.09 | ā5.38 | ā12.25 to 1.48 | 1.03āĀ±ā14.60 | ā3.64 | ā10.26 to 2.96 |
I | 2.00āĀ±ā24.43 | 3.86āĀ±ā19.03) | 2.83āĀ±ā18.44 |